Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity of SC...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Sociedade Brasileira de Genética
2004-01-01
|
| Series: | Genetics and Molecular Biology |
| Assuntos: | |
| Acceso en liña: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572004000100019 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|